开放期刊系统

NIS的表达与甲状腺癌的相关性分析

马 伟, 苏 鹏程, 艾力 ·赛丁

摘要

目的:通过研究甲状腺癌的的分子水平特征,研究其发病机制并找到有效的治疗方法。通过免疫组织化法对甲状腺癌的癌组织及正常甲状腺组织中NIS蛋白的检测,明确NIS的表达与甲状腺癌的相关性,为甲状腺癌的诊断、治疗、预后提供临床指导意义。方法:选取在我院2019年10月至2020年8月收治的符合甲状腺癌诊断标准并具有完整临床病理资料的患者50例(男性27例,女性23例;年龄9~80岁,中位年龄65岁)),将以上病例的正常甲状腺组织作为对照。对所有病例的临床病理资料进行回顾性分析,通过免疫组织化学方法处理,检测NIS蛋白在甲状腺癌组织及正常甲状腺组织中的表达情况,并比较其差异。结果:免疫组化结果显示:1.在50例甲状腺癌患者中,均未出现NIS阴性表达;甲状腺癌组织NIS蛋白弱阳性表达有49例(98%),在甲状腺癌旁组织中,NIS蛋白弱阳性表达有9例(18%),弱阳性表达率甲状腺癌显著高于甲状腺癌旁组织,差异具有统计学意义(P<0.05);2.在50例甲状腺癌患者中,甲状腺癌组织NIS蛋白阳性表达有1例(2%),在甲状腺癌旁组织中,NIS蛋白阳性表达有14例(28%),阳性表达率甲状腺癌显著低于甲状腺癌旁组织,差异具有统计学意义(P<0.05);3.在50例甲状腺癌患者中,NIS蛋白强阳性表达有0例(0%),在甲状腺癌旁组织中,NIS蛋白强阳性表达有27例(54%),强阳性表达率甲状腺癌显著低于甲状腺癌旁组织,差异具有统计学意义(P<0.05)。4.甲状腺癌NIS蛋白强阳性表达显著低于甲状腺癌旁组织。甲状腺癌NIS免疫组织化学染色产物主要定位在细胞质,且呈弥漫性、棕褐色深染;正常甲状腺NIS阳性产物定位于细胞膜和细胞质,呈淡黄色、分散性着色。结论:甲状腺癌中NIS蛋白表达弱阳性率显著高于甲状腺癌旁组织,而强阳性率明显低于甲状腺癌旁组织;甲状腺癌中NIS蛋白表达强阳性率较甲状腺癌旁组织显著降低;NIS功能蛋白定位于细胞膜, 在不同甲状腺疾病组织中的表达水平有所差异。

关键词

甲状腺癌;钠碘转运体;放射性碘治疗

全文:

PDF

参考

[1]Siegel R,Miller K,Jemal A,etal.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30. [2]Tiedje VI, Schmid KW, Weber F, et al. Differentiated thyroid cancer [J].Der Internist,2015,56(2):153-166. [3]Baumann E. Ueber das normale Vorkommen von Jod im Thierkörper. (I. Mittheilung)[J].Biological Chemistry, 1896,21(4):319-330. [4]Maxon HR,Thomas SR,Samaratunga RC.Dosimetric calculations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer[J].Thyroid,1997,7(2):183-187. [5]Levy O,Dai G,Riedel C,Ginter CS,etal.Characterization of the thyroid Na+ /I-symporter with an anti-COOH terminus antibody[J].PNAS,1997,94(11):5568–5573. [6]Kogai T,Endo T,Saito T,etal.Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells[J].Endocrinology,1997,138(6):2227-2232. [7]Kim S, Chung JK, Min HS,etal. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma[J]. Nucl Med Mol Imaging,2014(48):91-97. [8]Castro MR, Bergert ER, Beito TG, et al. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells[J].J Clin Endocrinol Metab.1999,84(8):2957-2962. [9]Dohan O,Baloch Z,Banrevi Z,et al.Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases[J].J.Clin.Endocrinol Metab,2001,86(6):2697-2700. [10]Smith VE,Read ML, Turnell S,et al. A novelmecha-nism of sodium iodide symporter repression in differentiated thyroid cancer[J].J Cell Sci2009122(Ptl8)3393-3402. [11] Leoni SG, Kimura ET, Santisteban P,et al. Regulation of thyroid oxidative state by thioredoxin reductase has a crucial role in thyroid responses to iodide excess[J]. Mol Endocrinol,2011,25(11)1924–1935. [12] Serrano-Nascimento C, Calil-Silveira J, Nunes MT. Posttranscriptional regulation of sodium-iodide symporter mRNA expression in the rat thyroid gland by acute iodide administration[J]. Am J Physiol Cell Physiol,2010,298(4):C893–99. [13] Boelaert K, Smith VE, Stratford AL, et al. PTTG and PBF repress the human sodium iodide symporter. Oncogene,2007,26(30):4344-4356. [14]Roepke T K, King EC, Reyna-Neyra A, et al. Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis[J].Nature Medicine,2009,15(10):1186-1194. [15]Abbott GW,Tai KK, Neverisky DL, et al. KCNQ1, KCNE2, and Na+-coupled solute transporters form reciprocally regulating complexes that affect neuronal excitability[J]. ence Signaling,2014,7(315):ra22. [16] Nicola JP, Carrasco N, Mario Amzel L. Physiological sodium concentrations enhance the iodide affinity of the Na+/I−symporter[J]. Nat Commun,2014,5(3):3948. [17]许建林,梁晓燕,南永刚,等.NIS蛋白在良恶性甲状腺疾病中的表达[J].现代肿瘤医学,2015, 000(018):2580-2583. [18]Dohan O,De La Vieja A, Paroder V, et al. The sodium/iodide symporter(NIS):characterization,regulation,and medical significance[J].Endocr Rev,2003,24(1):48-77. [19]Morari EC, Marcello MA, Guilhen ACT, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas[J].Clinical Endocrinology,2011,75(2):247-254. [20]Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid,2016,26(1):131-133. [21]Peyrottes I, Navarro V, Ondo-Mendez A, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers[J]. European Journal of Endocrinology,2009,160(2):215-225. [22]Wapnir IL, Matt VDR, Kent N, et al. Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections[J]. Journal of Clinical Endocrinology and Metabolism,2003,88(4):1880-1888.


(127 摘要 Views, 87 PDF Downloads)

Refbacks

  • 当前没有refback。